Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Use of solubilizers in preclinical formulations: Effect of Cremophor EL on the pharmacokinetic properties on early discovery compounds.

Liu B, Gordon WP, Richmond W, Groessl T, Tuntland T.

Eur J Pharm Sci. 2016 May 25;87:52-7. doi: 10.1016/j.ejps.2015.10.015. Epub 2015 Oct 20.

PMID:
26499309
2.

TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Croucher JL, Iyer R, Li N, Molteni V, Loren J, Gordon WP, Tuntland T, Liu B, Brodeur GM.

Cancer Chemother Pharmacol. 2015 Jan;75(1):131-41. doi: 10.1007/s00280-014-2627-1. Epub 2014 Nov 14.

3.

Discovery of trifluoromethyl(pyrimidin-2-yl)azetidine-2-carboxamides as potent, orally bioavailable TGR5 (GPBAR1) agonists: structure-activity relationships, lead optimization, and chronic in vivo efficacy.

Phillips DP, Gao W, Yang Y, Zhang G, Lerario IK, Lau TL, Jiang J, Wang X, Nguyen DG, Bhat BG, Trotter C, Sullivan H, Welzel G, Landry J, Chen Y, Joseph SB, Li C, Gordon WP, Richmond W, Johnson K, Bretz A, Bursulaya B, Pan S, McNamara P, Seidel HM.

J Med Chem. 2014 Apr 24;57(8):3263-82. doi: 10.1021/jm401731q. Epub 2014 Apr 4.

PMID:
24666203
4.

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials.

Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY.

J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26.

PMID:
23742252
5.

Interstrain differences of in vitro metabolic stability and impact on early drug discovery.

Richmond W, Wogan M, Isbell J, Gordon WP.

J Pharm Sci. 2010 Nov;99(11):4463-8. doi: 10.1002/jps.22179.

PMID:
20845445
6.

Snapshot PK: a rapid rodent in vivo preclinical screening approach.

Liu B, Chang J, Gordon WP, Isbell J, Zhou Y, Tuntland T.

Drug Discov Today. 2008 Apr;13(7-8):360-7. doi: 10.1016/j.drudis.2007.10.014. Epub 2007 Nov 26. Review.

PMID:
18405850
7.

Investigations of mechanisms of reactive metabolite formation from (R)-(+)-pulegone.

Nelson SD, McClanahan RH, Thomassen D, Gordon WP, Knebel N.

Xenobiotica. 1992 Sep-Oct;22(9-10):1157-64. Review.

PMID:
1441606
8.

Identification of urinary metabolites of 8-methyl-8-azabicyclo-[3,2,1] octan-3-yl 3,5-dichlorobenzoate (MDL 72,222) in the dog and monkey.

Gordon WP, Cheng H, Larsen DL, Ragner JA, Landmesser NG.

Drug Metab Dispos. 1992 Jul-Aug;20(4):596-602.

PMID:
1356741
9.
11.

Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques.

Rettenmeier AW, Howald WN, Levy RH, Witek DJ, Gordon WP, Porubek DJ, Baillie TA.

Biomed Environ Mass Spectrom. 1989 Mar;18(3):192-9.

PMID:
2496780
12.

Carcinogenicity of deuterium-labeled 1,2-dimethylhydrazine in mice.

Turusov VS, Lanko NS, Parfenov YD, Gordon WP, Nelson SD, Hillery PS, Keefer LK.

Cancer Res. 1988 Apr 15;48(8):2162-7.

13.

Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques.

Rettenmeier AW, Gordon WP, Barnes H, Baillie TA.

Xenobiotica. 1987 Oct;17(10):1147-57.

PMID:
3122428
14.

The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran.

Gordon WP, Huitric AC, Seth CL, McClanahan RH, Nelson SD.

Drug Metab Dispos. 1987 Sep-Oct;15(5):589-94.

PMID:
2891472
15.

Metabolism of 2-(2-thienyl)allylamine hydrochloride in the rat: identification of a novel metabolite.

Gordon WP, McCarthy JR, Chang SY.

Biochem Biophys Res Commun. 1987 May 29;145(1):575-80.

PMID:
3593353
16.
17.

Studies on the mechanism of acetamide hepatocarcinogenicity.

Dybing E, Søderlund EJ, Gordon WP, Holme JA, Christensen T, Becher G, Rivedal E, Thorgeirsson SS.

Pharmacol Toxicol. 1987 Jan;60(1):9-16.

PMID:
3550769
18.

Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.

Rettenmeier AW, Gordon WP, Prickett KS, Levy RH, Baillie TA.

Drug Metab Dispos. 1986 Jul-Aug;14(4):454-64.

PMID:
2873993
19.

Metabolic fate of valproic acid in the rhesus monkey. Formation of a toxic metabolite, 2-n-propyl-4-pentenoic acid.

Rettenmeier AW, Gordon WP, Prickett KS, Levy RH, Lockard JS, Thummel KE, Baillie TA.

Drug Metab Dispos. 1986 Jul-Aug;14(4):443-53.

PMID:
2873992
20.

Mechanistic studies of acetamide hepatocarcinogenicity.

Dybing E, Gordon WP, Søderlund EJ, Holme JA, Rivedal E, Thorgeirsson SS.

Adv Exp Med Biol. 1986;197:755-62. No abstract available.

PMID:
3532711
21.

Procarbazine spermatogenesis toxicity: deuterium isotope effects point to regioselective metabolism in mice.

Yost GS, Horstman MG, el Walily AF, Gordon WP, Nelson SD.

Toxicol Appl Pharmacol. 1985 Sep 15;80(2):316-22.

PMID:
4024121
22.

The genotoxicity of 2-bromoacrolein and 2,3-dibromopropanal.

Gordon WP, Søderlund EJ, Holme JA, Nelson SD, Iyer L, Rivedal E, Dybing E.

Carcinogenesis. 1985 May;6(5):705-9.

PMID:
4006056
23.
24.
25.

Genotoxicity studies with paracetamol.

Dybing E, Holme JA, Gordon WP, Søderlund EJ, Dahlin DC, Nelson SD.

Mutat Res. 1984 Oct;138(1):21-32.

PMID:
6387477
26.

Activation mechanism of tris(2,3-dibromopropyl)phosphate to the potent mutagen, 2-bromoacrolein.

Nelson SD, Omichinski JG, Iyer L, Gordon WP, Soderlund EJ, Dybing E.

Biochem Biophys Res Commun. 1984 May 31;121(1):213-9.

PMID:
6375666
27.

Variability in the determination of fraction metabolized in a triangular metabolic problem and its resolution with stable isotope methodology.

Lin H, Levy RH, Lane EA, Gordon WP.

J Pharm Sci. 1984 Feb;73(2):285-7. No abstract available.

PMID:
6707907
28.

Comparison of hepatic biotransformation and toxicity of allyl alcohol and [1,1-2H2]allyl alcohol in rats.

Patel JM, Gordon WP, Nelson SD, Leibman KC.

Drug Metab Dispos. 1983 Mar-Apr;11(2):164-6. No abstract available.

PMID:
6133723
29.

Mammalian drug metabolism.

Nelson SD, Gordon WP.

J Nat Prod. 1983 Jan;46(1):71-8.

PMID:
6854339
30.

Memory disorders in aphasia--I. Auditory immediate recall.

Gordon WP.

Neuropsychologia. 1983;21(4):325-39.

PMID:
6621861
31.

Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse.

Gordon WP, Forte AJ, McMurtry RJ, Gal J, Nelson SD.

Toxicol Appl Pharmacol. 1982 Sep 30;65(3):413-24. No abstract available.

PMID:
7157374
32.

Metabolic activation of hydrazines.

Nelson SD, Gordon WP.

Adv Exp Med Biol. 1981;136 Pt B:971-81. No abstract available.

PMID:
7344522
33.

Effects of three syllable durations using the melodic intonation therapy technique.

Laughlin SA, Naeser MA, Gordon WP.

J Speech Hear Res. 1979 Jun;22(2):311-20.

PMID:
491558
34.

Characterization of mephenytoin metabolites in human urine by gas chromatography and mass spectrometry.

Lynn RK, Bauer JE, Gordon WP, Smith RG, Griffin D, Thompson RM, Jenkins R, Gerber N.

Drug Metab Dispos. 1979 May-Jun;7(3):138-44.

PMID:
38083
35.

Seminal excretion, vaginal absorption, distribution and whole blood kinetics of d-methadone in the rabbit.

Swanson BN, Gordon WP, Lynn RK, Gerber N.

J Pharmacol Exp Ther. 1978 Aug;206(2):507-14.

PMID:
682129
36.

Dose dependent metabolism and enterohepatic recirculation of valproic acid in the rat.

Dickinson RG, Harland RC, Rodgers RM, Gordon WP, Lynn RK, Gerber N.

Proc West Pharmacol Soc. 1978;21:217-20a. No abstract available.

PMID:
358207
37.

Excretion of phenytoin into semen of rabbits and man. Comparison with plasma levels.

Swanson BN, Leger RM, Gordon WP, Lynn RK, Gerber N.

Drug Metab Dispos. 1978 Jan-Feb;6(1):70-4.

PMID:
23276
38.

New gas chromatogrphic assay for the quantification of methadone. Application in human and animal studies.

Lynn RK, Leger RM, Gordon WP, Olsen GD, Gerber N.

J Chromatogr. 1977 Jan 21;131:329-40.

PMID:
856855
39.

The secretion of methadone and its major metabolite in the gastric juice of humans: comparison with blood and salivary concentrations.

Lynn RK, Olsen GD, Leger RM, Gordon WP, Smith RG, Gerber N.

Drug Metab Dispos. 1976 Sep-Oct;4(5):504-9.

PMID:
10151
40.

Behavioral auditory function after transection of crossed olivo-cochlear bundle in the cat. II. Conditioned visual performance with intense white noise.

Igarashi M, Alford BR, Gordon WP, Nakai Y.

Acta Otolaryngol. 1974 May;77(5):311-7. No abstract available.

PMID:
4835630
41.

Behavioral auditory function after transection of crossed olivo-cochlear bundle in the cat. I. Pure-tone threshold and perceptual signal-to-noise ratio.

Igarashi M, Alford BR, Nakai Y, Gordon WP.

Acta Otolaryngol. 1972 Jun;73(6):455-66. No abstract available.

PMID:
5047110

Supplemental Content

Loading ...
Support Center